J&J tops list in commercializing drugs; Perrigo to sell copycat of AndroGel;

@FiercePharma: GSK to hack jobs in Europe where austerity has taken toll. Report | Follow @FiercePharma

@EricPFierce: With sale of Tysabri rights to Biogen Idec, Elan is now flush with cash and looking for something to buy. News | Follow @EricPFierce

@AlisonBFierce: Merck and GlaxoSmithKline will work with the GAVI Alliance to provide low-cost HPV vaccines to developing countries. Article | Follow @AlisonBFierce

> Danish drugmaker Lundbeck, which earlier had warned that earnings would be restrained, today said higher costs cut deeply into its bottom line. Story

> A court has said that Forest Laboratories ($FRX) has pushed back an effort to create a class action out of litigation that claims the company was not forthright in its marketing of antidepressants Celexa and Lexapro to patients under the age of 18. News

> Perrigo ($PRGO) says it has gotten FDA approval to make an equivalent version of AbbVie's ($ABBV) testosterone med, AndroGel. Release

> Elite Pharmaceuticals says the FDA has given it approval to begin manufacturing a generic of Duramed's Revia opioid painkiller. Item

> A new report from IDEA Pharma says Johnson & Johnson ($JNJ) has had the most success getting drugs to market and then money to shareholders. Report

Medical Device News

 @FierceMedDev: Exosome draws $5M in financing for molecular Dx work. Item | Follow @FierceMedDev

 @MarkHFierce: House Majority Leader Eric Cantor has revived the device tax repeal push, as part of Republicans' new platform. Story | Follow @MarkHFierce

 @DamianFierce: Allergan is looking to sell off its Lap-Band business as revenues continue to plummet. News | Follow @DamianFierce

> HeartMate sales propel Thoratec's Q4 revenue jump. Article

> Zoll gains Japan's sign-off for intravascular temperature management device. Report

Biotech News

 @FierceBiotech: Pfizer partner Protalix soars on sale speculation. Report | Follow @FierceBiotech

@JohnCFierce: So Elan has $3.25B to play with? Will they blow it? Analysis | Follow @JohnCFierce

@RyanMFierce: No surprise here. HISUN doesn't want exclusive license to Celsion's ThermoDox for the China market. Release | Follow @RyanMFierce

> Catabasis raises $9M for PhII-ready drug development program. News

> Ipsen, insolvent biotech partner find buyer for troubled hemophilia drug. Report

Drug Delivery News

> Cloaked nanoparticles look like blood cells, carry drugs. Story

> FDA to review BTG's varicose vein foam injection. News

> Rockwell shows iron delivery drug for dialysis improves treatment. Article

> Langer's Kala scores Cystic Fibrosis Foundation grant. Report

Biomarkers News

> Brain biomarker may help open door to personalized depression drugs. Report

> FDA will make use of GVK biomarker database. Item

> Biomarker could be key to MS Dx and targeted treatment. Article

> Molecules that could predict cancer growth detected. News

> Researcher names protein as plausible autism biomarker. Story

And Finally... A study of medical students who attended schools with strict bans on taking gifts hit the streets being less likely to be influenced by drugmakers. More

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.